Elias Karam,
Auhtors: Benoist Chibaudel, Morteza Raeisi, Romain Cohen, Greg Yothers, Richard M. Goldberg, Jean-Baptiste Bachet, Norman Wolmark, Takayuki Yoshino, Hans-Joachim Schmoll, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham-Shmueli, Qian Shi, Thierry André, Aimery de Gramont.
“ACCENT pooled analysis published in JCO:
No benefit of OX was observed for OS in either the low-risk or even in high-risk patient subgroup, stage II colon cancer
OX should not be anymore our standard of care even in high risk stage II colon cancer population.
FP (CAPE or 5-FU) does the job.”
Source: Elias Karam/LinkedIn